Montelukast Sodium is essentially useless in patients with emphysema.
Montelukast sodium a leukotriene receptor antagonist, its mechanism of action is through the inhibition of leukotriene biological activity and anti-inflammatory effect, at the same time can be diastolic bronchial smooth muscle. It is particularly indicated for the treatment of patients with aspirin asthma, exercise asthma and asthma with allergic rhinitis. It can reduce the dosage of other drugs such as glucocorticoids and salbutamol when combined with these drugs.
In patients with emphysema, the presence of emphysema is not usually treated if it does not affect lung function or if the effect on lung function is very small.
When it significantly affects lung function, when it is mostly combined with chronic obstructive pulmonary disease, the drugs used are glucocorticosteroids such as prednisone, bronchodilators such as salbutamol and formoterol, anticholinergics such as ipratropium bromide, and other drugs such as home oxygen therapy.
Patients with emphysema need to seek timely medical attention, and the above drugs need to be standardized and rationally applied under the guidance of professional physicians and pharmacists.